EU Biosimilar Action: New Competitors For Remicade/Herceptin, Four More Products Await CHMP OK

 
• By Ian Schofield

Two more biosimilar medicines have been approved in the EU: Sandoz’s Zessly (infliximab) and Amgen’s Kanjinti (trastuzumab). Four other biosimilars are expecting a CHMP opinion this week, including three versions of AbbVie's Humira.

Approved
The EU has approved more biosimilar versions of Remicade and Herceptin

More from Approvals

More from Product Reviews